{"id":5254,"date":"2026-03-27T10:59:56","date_gmt":"2026-03-27T10:59:56","guid":{"rendered":"https:\/\/cognitionconferences.com\/hivaids\/?post_type=speaker&p=5254"},"modified":"2026-03-27T11:05:34","modified_gmt":"2026-03-27T11:05:34","slug":"jikun-zhou","status":"publish","type":"speaker","link":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/","title":{"rendered":"Jikun Zhou"},"content":{"rendered":"

Abstract:<\/strong><\/p>\n

Methods\uff1a This study employed a retrospective cohort design, selecting HIV\/AIDS patients who first received antiretroviral therapy at the Fifth Hospital of Shijiazhuang from January 2016 to December 2018 as the research subjects. Categorical data were described using frequency and percentage (%). The Wilcoxon rank-sum test was utilized to compare differences in continuous variables between two groups. The chi-square test or Fisher’s exact test was applied to analyze differences in composition ratios between groups, and a multivariate logistic regression model was used to explore factors influencing the effectiveness of various ART regimens. Additionally, generalized estimating equations were employed to compare CD4\/CD8 cell ratios at different treatment time points among HIV\/AIDS patients while assessing risk factors for elevated alanine aminotransferase levels and abnormal blood glucose.<\/p>\n

Results \uff1a 1. The majority of the patients were under 50 years old. Most of them were unmarried and had a majority of those with college degree or above. The predominant mode of transmission within this cohort was homosexual contact. At baseline, the majority of patients were classified as WHO clinical stage I and II, with CD4+ T lymphocyte counts below 200 cells\/\u03bcL, a baseline CD4\/CD8 ratio \u2264 0.3, and a high proportion receiving the initial treatment regimen comprising tenofovir disoproxil fumarate, lamivudine (3TC), and efavirenz . Furthermore, after 12 months on ART, these HIV\/AIDS patients exhibited an upward trend in both CD4+ T lymphocyte counts and CD4\/CD8 ratios. 2.In this study, HIV\/AIDS patients initiating ART demonstrated favorable immunological recovery outcomes. Notably, those with CD4+ T lymphocyte counts below 200 cells\/\u03bcL showed better immunological recovery compared to individuals with counts between 200 cells\/\u03bc L and less than 350 cells\/\u03bc L as well as those with counts equal to or greater than 350 cells\/ \u03bc L. 3. After undergoing 12 months of ART, HIV\/AIDS patients displayed effective viral load suppression. For individuals with CD4+ T lymphocyte counts ranging from 200 to less than 350 cells\/\u03bcL and those\u2265 350 cells\/\u03bc L, viral load suppression was significantly superior compared to that observed in patients with CD4+ T lymphocyte counts below 200 cells\/ \u03bc L; additionally, among various treatment regimens evaluated, those starting on TDF +3TC + EFV achieved better viral load suppression outcomes. 4. Following twelve months of ART treatment for HIV\/AIDS patients resulted in a low proportion achieving normalized CD4\/CD8 ratios. Married individuals or those with partners exhibited more favorable restoration of their CD4\/CD8 ratios compared to unmarried counterparts; moreover, at baseline assessment where the CD4\/CD8 ratio exceeded 0.3 demonstrated significantly superior recovery relative to populations whose baseline ratios were \u2264 0.3. 5. After twelve months on ART therapy for HIV\/AIDS patients revealed a low rate of complete immune reconstitution; furthermore, having a baseline CD4\/CD8 ratio \u2264 0.3 is considered a risk factor adversely affecting immune reconstitution in these individuals.
\nConclusion: <\/strong>The HIV\/AIDS patients included in this study have demonstrated favorable outcomes in antiretroviral therapy, with significant improvements in immunological recovery and viral suppression. However, the normalization of the CD4\/CD8 cell ratio and the proportion of patients achieving complete immune reconstitution remain relatively low. Additionally, some patients exhibit abnormal biochemical indicators following ART. Therefore, it is essential to enhance monitoring of relevant biochemical parameters for long-term ART recipients, improve patient adherence, optimize related ART regimens, and actively pursue symptomatic treatment to elevate the quality of life for these patients.<\/p>\n

Biography :\u00a0<\/strong>
\nZhou Jikun is an epidemiologist and chief physician, graduated from China Union Medical University, and was a visiting scholar at the U.S. Centers for Disease Control and Prevention. He is currently the deputy director of the Fifth Hospital of Shijiazhuang and a master’s supervisor in epidemiology and health statistics at Hebei Medical University.
\nObjective \uff1a This study explores the basic characteristics of the first antiviral treatment for HIV\/AIDS patients; analyzes the risk factors affecting the therapeutic efficacy after ART treatment, as well as the risk factors causing abnormal biochemical indicators in patients.<\/p>\n","protected":false},"featured_media":5260,"template":"","meta":{"_acf_changed":false},"schedule":[5],"speaker-category":[6],"class_list":["post-5254","speaker","type-speaker","status-publish","has-post-thumbnail","hentry","schedule-day-1","speaker-category-speakers"],"acf":[],"yoast_head":"\nJikun Zhou | Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University. | China<\/title>\n<meta name=\"description\" content=\"Zhou Jikun is an epidemiologist and chief physician, graduated from China Union Medical University, and was a visiting scholar at the U.S. Centers for Disease Control and Prevention. He is currently the deputy director of the Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University.Objective \uff1a This study explores the basic characteristics of the first antiviral treatment for HIV\/AIDS patients; analyzes the risk factors affecting the therapeutic efficacy after ART treatment, as well as the risk factors causing abnormal biochemical indicators in patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jikun Zhou | Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University. | China\" \/>\n<meta property=\"og:description\" content=\"Zhou Jikun is an epidemiologist and chief physician, graduated from China Union Medical University, and was a visiting scholar at the U.S. Centers for Disease Control and Prevention. He is currently the deputy director of the Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University.Objective \uff1a This study explores the basic characteristics of the first antiviral treatment for HIV\/AIDS patients; analyzes the risk factors affecting the therapeutic efficacy after ART treatment, as well as the risk factors causing abnormal biochemical indicators in patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/\" \/>\n<meta property=\"og:site_name\" content=\"Cognition Conferences\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-27T11:05:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cognitionconferences.com\/hivaids\/wp-content\/uploads\/2026\/03\/Jikun-Zhou-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"240\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/speaker\\\/jikun-zhou\\\/\",\"url\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/speaker\\\/jikun-zhou\\\/\",\"name\":\"Jikun Zhou | Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University. | China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/speaker\\\/jikun-zhou\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/speaker\\\/jikun-zhou\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Jikun-Zhou-1.png\",\"datePublished\":\"2026-03-27T10:59:56+00:00\",\"dateModified\":\"2026-03-27T11:05:34+00:00\",\"description\":\"Zhou Jikun is an epidemiologist and chief physician, graduated from China Union Medical University, and was a visiting scholar at the U.S. Centers for Disease Control and Prevention. He is currently the deputy director of the Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University.Objective \uff1a This study explores the basic characteristics of the first antiviral treatment for HIV\\\/AIDS patients; analyzes the risk factors affecting the therapeutic efficacy after ART treatment, as well as the risk factors causing abnormal biochemical indicators in patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/speaker\\\/jikun-zhou\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/speaker\\\/jikun-zhou\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/speaker\\\/jikun-zhou\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Jikun-Zhou-1.png\",\"contentUrl\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Jikun-Zhou-1.png\",\"width\":200,\"height\":240},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/speaker\\\/jikun-zhou\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jikun Zhou\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/#website\",\"url\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/\",\"name\":\"Cognition Conferences\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cognitionconferences.com\\\/hivaids\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jikun Zhou | Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University. | China","description":"Zhou Jikun is an epidemiologist and chief physician, graduated from China Union Medical University, and was a visiting scholar at the U.S. Centers for Disease Control and Prevention. He is currently the deputy director of the Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University.Objective \uff1a This study explores the basic characteristics of the first antiviral treatment for HIV\/AIDS patients; analyzes the risk factors affecting the therapeutic efficacy after ART treatment, as well as the risk factors causing abnormal biochemical indicators in patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/","og_locale":"en_US","og_type":"article","og_title":"Jikun Zhou | Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University. | China","og_description":"Zhou Jikun is an epidemiologist and chief physician, graduated from China Union Medical University, and was a visiting scholar at the U.S. Centers for Disease Control and Prevention. He is currently the deputy director of the Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University.Objective \uff1a This study explores the basic characteristics of the first antiviral treatment for HIV\/AIDS patients; analyzes the risk factors affecting the therapeutic efficacy after ART treatment, as well as the risk factors causing abnormal biochemical indicators in patients.","og_url":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/","og_site_name":"Cognition Conferences","article_modified_time":"2026-03-27T11:05:34+00:00","og_image":[{"width":200,"height":240,"url":"https:\/\/cognitionconferences.com\/hivaids\/wp-content\/uploads\/2026\/03\/Jikun-Zhou-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/","url":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/","name":"Jikun Zhou | Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University. | China","isPartOf":{"@id":"https:\/\/cognitionconferences.com\/hivaids\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/#primaryimage"},"image":{"@id":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/#primaryimage"},"thumbnailUrl":"https:\/\/cognitionconferences.com\/hivaids\/wp-content\/uploads\/2026\/03\/Jikun-Zhou-1.png","datePublished":"2026-03-27T10:59:56+00:00","dateModified":"2026-03-27T11:05:34+00:00","description":"Zhou Jikun is an epidemiologist and chief physician, graduated from China Union Medical University, and was a visiting scholar at the U.S. Centers for Disease Control and Prevention. He is currently the deputy director of the Fifth Hospital of Shijiazhuang and a master's supervisor in epidemiology and health statistics at Hebei Medical University.Objective \uff1a This study explores the basic characteristics of the first antiviral treatment for HIV\/AIDS patients; analyzes the risk factors affecting the therapeutic efficacy after ART treatment, as well as the risk factors causing abnormal biochemical indicators in patients.","breadcrumb":{"@id":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/#primaryimage","url":"https:\/\/cognitionconferences.com\/hivaids\/wp-content\/uploads\/2026\/03\/Jikun-Zhou-1.png","contentUrl":"https:\/\/cognitionconferences.com\/hivaids\/wp-content\/uploads\/2026\/03\/Jikun-Zhou-1.png","width":200,"height":240},{"@type":"BreadcrumbList","@id":"https:\/\/cognitionconferences.com\/hivaids\/speaker\/jikun-zhou\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cognitionconferences.com\/hivaids\/"},{"@type":"ListItem","position":2,"name":"Jikun Zhou"}]},{"@type":"WebSite","@id":"https:\/\/cognitionconferences.com\/hivaids\/#website","url":"https:\/\/cognitionconferences.com\/hivaids\/","name":"Cognition Conferences","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cognitionconferences.com\/hivaids\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/cognitionconferences.com\/hivaids\/wp-json\/wp\/v2\/speaker\/5254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cognitionconferences.com\/hivaids\/wp-json\/wp\/v2\/speaker"}],"about":[{"href":"https:\/\/cognitionconferences.com\/hivaids\/wp-json\/wp\/v2\/types\/speaker"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cognitionconferences.com\/hivaids\/wp-json\/wp\/v2\/media\/5260"}],"wp:attachment":[{"href":"https:\/\/cognitionconferences.com\/hivaids\/wp-json\/wp\/v2\/media?parent=5254"}],"wp:term":[{"taxonomy":"schedule","embeddable":true,"href":"https:\/\/cognitionconferences.com\/hivaids\/wp-json\/wp\/v2\/schedule?post=5254"},{"taxonomy":"speaker-category","embeddable":true,"href":"https:\/\/cognitionconferences.com\/hivaids\/wp-json\/wp\/v2\/speaker-category?post=5254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}